研究单位：[1]Biotheus Inc.[2]Jilin Cancer Hospital,Changchun,Jilin,China[3]Affiliated Hospital of Nantong University,Nantong,Jiangsu,China[4]The First Affiliated Hospital Of Ningbo University,Ningbo,Zhejiang,China[5]Binzhou Medical University Hospital,Binzhou,China[6]Hunan Cancer Hospital,Changsha,China[7]Sichuan Cancer Hospital,Chengdu,China[8]First People''s Hospital of Chenzhou,Chenzhou,China[9]The First Affiliated Hospital of Army Medical University,Chongqing,China[10]The Second Hospital of Dalian Medical University,Dalian,China[11]The First People''s Hospital of Foshan,Foshan,China[12]Fujian Cancer Hospital,Fuzhou,China[13]The Affiliated Hospital Of Guilin Medical University,Guilin,China[14]Zhejiang Cancer Hospital,Hangzhou,China[15]Harbin Medical University Cancer Hospital,Harbin,China[16]Anhui Province Hospital,Hefei,China[17]Shandong Cancer Institute,Jinan,China[18]Jingzhou First People''s Hospital,Jingzhou,China[19]Affiliated Hospital of Jining Medical University,Jining,China[20]Yunnan Cancer Hospital,Kunming,China[21]Liuzhou People''s Hospital,Liuzhou,China[22]The First Affiliated Hospital of Henan University of Science & Technology,Luoyang,China[23]Meizhou People''s Hospital,Meizhou,China[24]Mianyang Central Hospital,Mianyang,China[25]Jiangxi Cancer Hospital,Nanchang,China[26]The First Affiliated Hospital of Nanchang University,Nanchang,China[27]Nanchong Central Hospital,Nanchong,China[28]Jiangsu Province Hospital,Nanjing,China[29]Nanjing Drum-Tower Hospital,Nanjing,China[30]Guangxi Medical University Cancer Hospital,Nanning,China[31]Nanyang Central Hospital,Nanyang,China[32]Qujing NO.1 Hospital,Qujing,China[33]The Fourth Hospital of Hebei Medical University,Shijia Zhuang,China[34]Taizhou Enze Medical Center (group),Taizhou,China[35]Weifang NO.2 People''s Hospital,Weifang,China[36]Weihai Municipal Hospital,Weihai,China[37]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China[38]Zhongnan Hospital Of Wuhan University,Wuhan,China[39]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,China[40]Xiangyang Central Hospital,Xiangyang,China[41]Xuzhou Central Hospital,Xuzhou,China[42]The Second People''s Hospital Of Yibin,Yibin,China[43]Yongzhou Central Hospital,Yongzhou,China[44]Yuncheng City Center Hospital,Yuncheng,China[45]Zhangzhou Municipal Hospital of Fujian Province,Zhangzhou,China[46]Zhoukou Central Hospital,Zhoukou,China
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC
